BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 38685100)

  • 1. The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.
    Abad E; Sandoz J; Romero G; Zadra I; Urgel-Solas J; Borredat P; Kourtis S; Ortet L; Martínez CM; Weghorn D; Sdelci S; Janic A
    J Exp Clin Cancer Res; 2024 Apr; 43(1):127. PubMed ID: 38685100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.
    Alidousty C; Baar T; Martelotto LG; Heydt C; Wagener S; Fassunke J; Duerbaum N; Scheel AH; Frank S; Holz B; Binot E; Kron A; Merkelbach-Bruse S; Ihle MA; Wolf J; Buettner R; Schultheis AM
    J Pathol; 2018 Sep; 246(1):67-76. PubMed ID: 29885057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNF144B-mediated p21 degradation regulated by HDAC3 contribute to enhancing ovarian cancer growth and metastasis.
    Zhuang H; Zhang Z; Wang W; Qu H
    Tissue Cell; 2024 Feb; 86():102277. PubMed ID: 37992458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation.
    Yang G; Gong Y; Wang Q; Wang L; Zhang X
    Oncogene; 2017 Feb; 36(8):1023-1037. PubMed ID: 27524417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
    Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
    Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide Screens Implicate Loss of Cullin Ring Ligase 3 in Persistent Proliferation and Genome Instability in TP53-Deficient Cells.
    Drainas AP; Lambuta RA; Ivanova I; Serçin Ö; Sarropoulos I; Smith ML; Efthymiopoulos T; Raeder B; Stütz AM; Waszak SM; Mardin BR; Korbel JO
    Cell Rep; 2020 Apr; 31(1):107465. PubMed ID: 32268084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Janus Face of p53-Targeting Ubiquitin Ligases.
    Hao Q; Chen Y; Zhou X
    Cells; 2020 Jul; 9(7):. PubMed ID: 32660118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model.
    Liang Y; Gao H; Lin SY; Goss JA; Du C; Li K
    Oncogene; 2015 Aug; 34(33):4368-78. PubMed ID: 25362854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer.
    Calcagno DQ; Freitas VM; Leal MF; de Souza CR; Demachki S; Montenegro R; Assumpção PP; Khayat AS; Smith Mde A; dos Santos AK; Burbano RR
    BMC Gastroenterol; 2013 Sep; 13():141. PubMed ID: 24053468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The E3 ubiquitin ligase RNF144B is LPS-inducible in human, but not mouse, macrophages and promotes inducible IL-1β expression.
    Ariffin JK; Kapetanovic R; Schaale K; Gatica-Andrades M; Blumenthal A; Schroder K; Sweet MJ
    J Leukoc Biol; 2016 Jul; 100(1):155-61. PubMed ID: 26819317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of the expression and prognosis for RBR E3 ubiquitin ligases in lung adenocarcinoma.
    Ding H; Wang Y; Cui Y; Chen Z; Li Y; Yang J; Yang Y; Chen T; Xia D; Li C; Xu C; Ding C; Zhao J
    Thorac Cancer; 2022 Sep; 13(17):2459-2472. PubMed ID: 35820682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pir2/Rnf144b is a potential endometrial cancer biomarker that promotes cell proliferation.
    Zhou Q; Eldakhakhny S; Conforti F; Crosbie EJ; Melino G; Sayan BS
    Cell Death Dis; 2018 May; 9(5):504. PubMed ID: 29724995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53.
    Yang D; Cheng D; Tu Q; Yang H; Sun B; Yan L; Dai H; Luo J; Mao B; Cao Y; Yu X; Jiang H; Zhao X
    Theranostics; 2018; 8(13):3517-3529. PubMed ID: 30026863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
    Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
    Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer.
    Li K; Zheng X; Tang H; Zang YS; Zeng C; Liu X; Shen Y; Pang Y; Wang S; Xie F; Lu X; Luo Y; Li Z; Bi W; Jia X; Huang T; Wei R; Huang K; Chen Z; Zhu Q; He Y; Zhang M; Gu Z; Xiao Y; Zhang X; Fletcher JA; Wang Y
    J Exp Med; 2021 Aug; 218(8):. PubMed ID: 34143182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity.
    Chinnam M; Xu C; Lama R; Zhang X; Cedeno CD; Wang Y; Stablewski AB; Goodrich DW; Wang X
    PLoS Genet; 2022 May; 18(5):e1010171. PubMed ID: 35588102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LINC00662 triggers malignant progression of chordoma by the activation of RNF144B via targeting miR-16-5p.
    Wang CB; Wang Y; Wang JJ; Guo XL
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1007-1022. PubMed ID: 32096180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
    Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
    J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome Inhibition Overcomes ALK-TKI Resistance in
    Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
    Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.